

1 Original article

2 **Pharmacokinetics-based identification of antiviral**
3 **compounds of *Rheum palmatum* rhizomes and roots**
4 **(Dahuang)**

5 Nan-Nan Tian^{a,b,1}, Ling-Ling Ren^{b,c,1}, Ya-Xuan Zhu^{a,b,1}, Jing-Ya Sun^{d,1},
6 Jun-Lan Lu^{a,b}, Jia-Kai Zeng^b, Feng-Qing Wang^b, Fei-Fei Du^b, Xi-He
7 Yang^{b,c}, Shu-Ning Ge^d, Rui-Min Huang^{d,***}, Wei-Wei Jia^{b,**}, Chuan
8 Li^{a,b,c,e,*}

9 ^a*Graduate School, Tianjin University of Traditional Chinese Medicine, Tianjin,*
10 *300193, China*

11 ^b*State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica,*
12 *Chinese Academy of Sciences, Shanghai, 201203, China*

13 ^c*School of Pharmacy, University of Chinese Academy of Sciences, Beijing, 100049,*
14 *China*

15 ^d*Center for Drug Safety Evaluation and Research, Shanghai Institute of Materia*
16 *Medica, Chinese Academy of Sciences, Shanghai, 201203, China*

17 ^e*Haihe Laboratory of Modern Chinese Medicine, Tianjin 301617, China*

18

19

20

21

22 * Corresponding author.

23 State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica,
24 Chinese Academy of Sciences, Shanghai, 201203, China.

25 ** Corresponding author.

26 *** Corresponding author.

27 *E-mail addresses:* rmhuang@simm.ac.cn (R-M. Huang), weiweijia@simm.ac.cn

28 (W-W. Jia), chli@simm.ac.cn (C. Li).

29 ¹ These authors contributed equally to this work.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

30 **Abstract**

31 The potential of Dahuang to eliminate lung pathogens was often highlighted in
32 *Wenyi Lun*. This investigation aimed to identify potential antiviral compounds of
33 herbal component Dahuang (*Rheum palmatum* rhizomes and roots) of
34 LianhuaQingwen capsule, with respect to their systemic exposure and lung
35 reachability. Circulating Dahuang compounds were identified in human volunteers
36 receiving LianhuaQingwen. The reachability of these compounds to SARS-CoV-2
37 3CL^{pro} was assessed by *in vitro* transport, metabolism, immunohistochemistry, and
38 3CL^{pro}-biochemical studies. LianhuaQingwen contained 55 Dahuang constituents
39 (0.01–2.08 μmol/day), categorized into eight classes. Only three compounds rhein (**3**),
40 methylisorhein (**10**; a new Dahuang anthraquinone), and 4-*O*-methylgallic acid
41 (**M42M₂**) exhibited significant systemic exposure in humans. Two intestinal
42 absorption mechanisms for **3** and **10** were proposed: active intestinal uptake of **3/10**
43 by human TAUT/ASBT and human MRP1/3/4, and intestinal lactate-phlorizin
44 hrdolyase-mediated hydrolysis of rhein-8-*O*-β-D-glucoside (**9**), followed by the
45 transporter-mediated absorption of released **3**. Targeted reachability of circulating
46 **3/10** could be achieved as rat orthologues of human ASBT/TAUT was observed in
47 alveolar and bronchial epithelia. These compounds exhibited potential ability to
48 inhibit the 3CL^{pro} enzyme responsible for coronaviral replication. Notably, Dahuang
49 anthraquinones and tannins varied greatly in pharmacokinetics between humans and
50 rats after dosing LianhuaQingwen. This investigation, along with such investigations
51 of other components, has implications for precisely defining the therapeutic benefits
52 of Dahuang-containing medicines.

53

54

55 **Abbreviations:** 3CL^{pro}, 3-chymotrypsin-like protease; ASBT/Asbt, apical
56 sodium-dependent bile acid transporter; TAUT/Taut, taurine transporter.

57

58

59

60 **Keywords:** Rhein; methylisorhein; *Rheum palmatum*; Dahuang; Rhubarb;
61 LianhuaQingwen; 3CL^{pro}; COVID-19

62 1. Introduction

63 Dahuang (Rhubarb) has been used in traditional Chinese medicine for over 2000
64 years. Its medicinal properties and various applications were first recorded in the
65 *Divine Husbandman's Classic of Materia Medica (Shen Nong Ben Cao Jing)* during
66 the Han Dynasty. The medicinal herb is obtained from the dried roots and rhizomes of
67 three species: *Rheum palmatum* L., *Rheum tanguticum* Maxim. ex Balf., and *Rheum*
68 *officinale* Baill, which are included in the 2020 Chinese Pharmacopeia [1, 2].
69 According to the *Epidemic Febrile Disease (Wenyi Lun)* in the Ming Dynasty,
70 Dahuang was used to eliminate pestilential qi due to its penetrating properties without
71 detainment [3]. This theory proposed that "epidemic disease" was caused by the
72 infection of pestilential qi, which referred to an exogenous disease pathogen that was
73 highly contagious and had an unpredictable epidemic pattern. Modern research
74 provided evidence suggesting that Dahuang extracts possessed inhibitory activity
75 against the 3-chymotrypsin-like protease (3CL^{pro}) of severe acute respiratory
76 syndrome coronavirus (SARS-CoV) [4]. Furthermore, an integrated computational
77 study revealed that 13 natural anthraquinones, including chrysophanol, emodin,
78 aloe-emodin, rhein, and alterporriol Q, exhibited promising potential as inhibitors of
79 3CL^{pro} of SARS-CoV-2 [5]. The application and findings indicated that Dahuang
80 compounds might possess promising antiviral properties in humans. Additionally, the
81 rapid development of modern science unraveled numerous pharmacological activities
82 associated with Dahuang, including its purgative effects, anti-inflammatory properties,
83 hepatoprotective benefits, and positive impacts on the gallbladder. Dahuang was used
84 in clinical settings to treat constipation, severe acute pancreatitis, sepsis, and chronic
85 liver and kidney diseases due to its extensive pharmacological effects [1, 6-8].

86 Dahuang has mainly been used for medicinal purposes in Asia, but it often refers to a
87 few edible Dahuang in Europe and the Middle East [6, 7]. Concerns regarding the
88 safety of Dahuang have arisen due to reports suggesting potential liver and kidney
89 toxicity associated with long-term high-dose administration of Dahuang in rats,
90 prompting global scrutiny on its safety profile [1, 6, 9].

91 LianhuaQingwen capsule, a traditional Chinese medicine that contains Dahuang,
92 has been widely used in China for the treatment of acute respiratory viral infections
93 caused by various viruses, including SARS-CoV, MERS-CoV, influenza A virus
94 (including H1N1 and H7N9), and more recently, SARS-CoV-2 [10, 11]. Several
95 clinical investigations reported the potential of the capsule as a valuable treatment
96 option for both COVID-19 and influenza patients. Its ability to improve viral
97 clearance, alleviate symptoms, and reduce inflammatory markers makes it a
98 promising addition to conventional care [12-16]. In a recent prospective, multicenter,
99 randomized controlled trial of 284 patients with COVID-19, adding LianhuaQingwen
100 to conventional care further improved the recovery rate of symptoms, shortened the
101 time to symptom recovery, and improved the recovery of chest radiologic
102 abnormalities ($P < 0.05$ for all) [12]. Treatment of the capsule in influenza patients
103 was found to reduce the levels of serum inflammatory factors C-reactive protein, IL-6,
104 and procalcitonin [16]. In a cell-based study, LianhuaQingwen demonstrated
105 inhibition of SARS-CoV-2 replication and induced abnormal particle morphology of
106 the virion [17]. Additionally, several circulating constituents of LianhuaQingwen,
107 including rhein, forsythoside A, forsythoside I, and neochlorogenic acid, were
108 identified as inhibitors of the host target cell-surface protein known as angiotensin
109 converting enzyme 2 receptor [18], to which the SARS-CoV-2 spike protein binds.

110 LianhuaQingwen capsule is derived from 13 herbal components and possesses

111 complex chemical composition. For systemic treatment of acute respiratory viral
112 infection with LianhuaQingwen, identification of circulating compounds in
113 unchanged and/or metabolized forms is vital for facilitating their access to the loci
114 responsible for therapeutic effects. To this end, comprehensive understanding of
115 chemical composition of LianhuaQingwen and better evaluation of pharmacokinetics,
116 disposition, and targeted reachability of its bioavailable compounds are vital for
117 translating the potential benefits of the capsule into therapeutic application.
118 Successful identification of such constituents necessitates a comprehensive approach
119 to the multi-compound pharmacokinetic investigation of herbal medicine such that the
120 potentially important herbal compounds are singled out with their accurate
121 pharmacokinetic and disposition data and that no such compound is missed (in a few
122 words, ‘precision without omission’) [19-30]. In our ongoing series of
123 multi-compound pharmacokinetic investigations on LianhuaQingwen, we have
124 previously conducted research on the constituents originating from the herbal
125 component Gancao in humans after dosing the capsule [20]. In this current
126 investigation, our focus is on the component Dahuang, with the aim of identifying the
127 compounds that are likely to have therapeutic significance. Dahuang is extensively
128 used as an herb in Chinese herbal medicines as well as dietary products. Therefore,
129 further research is necessary to elucidate the specific compounds responsible for its
130 pharmacological effects. This research has important implications for the safe
131 utilization of Dahuang-containing herbal medicines. Specifically, this
132 pharmacokinetic investigation aimed to identify bioavailable Dahuang compounds
133 that have systemic exposure and targeted reachability, and are likely to influence the
134 therapeutic outcomes of Dahuang-containing herbal medicines, such as
135 LianhuaQingwen.

136 **2. Materials and methods**

137 A detailed description of materials and experimental procedures is provided in the
138 [Supplementary Materials and methods](#).

139 *2.1. Study materials*

140 LianhuaQingwen capsules are produced by Shijiazhuang Yiling Pharmaceutical
141 Co., Ltd and have a Chinese NMPA drug ratification number of
142 GuoYaoZhunZi-Z20040063. Samples of LianhuaQingwen capsules were obtained
143 from the manufacturer, along with individual samples of the herbal components, and
144 stored at -20°C until analysis to assess their chemical composition and lot-to-lot
145 variability. Purified compounds found in *Rheum* species were obtained commercially
146 ([Table S1](#)). One such compound, 3,8-dihydroxy-1-methylanthraquinone-2-carboxylic
147 acid (methylisorhein), was extracted and isolated from Dahuang (*R. palmatum*
148 rhizomes and roots) ([Table S2](#)).

149 Caco-2 cells and HEK-293 cells were obtained from American Type Culture
150 Collection (Manassas, VA, USA). Various human transporter cDNAs and human
151 enzyme cDNA lactase-phlorizin hydrolase (LPH) were constructed commercially.
152 Inside-out membrane vesicles expressing human ATP-binding cassette transporter
153 were purchased from GenoMembrane (Kanazawa, Japan). Pooled human liver
154 microsomes (HLM) and pooled human liver cytosol (HLC) were obtained from
155 Corning Gentest (Woburn, MA, USA). Commercially available positive substrates for
156 these transporters and enzymes were also obtained.

157 *2.2. Human pharmacokinetic study*

158 A pharmacokinetic study on LianhuaQingwen capsule was conducted at Hebei
159 Yiling Hospital (Shijiazhuang, Hebei Province, China). The study was approved by
160 the hospital's ethics committee and registered with the Chinese Clinical Trials
161 Registry (ChiCTR1900021460), following the Declaration of Helsinki. Fourteen
162 healthy volunteers participated in the study after providing written informed consent.
163 The study details have been previously described [20]. Briefly, the participants
164 received a single dose of 12 capsules of LianhuaQingwen on day 1 and days 3-8.
165 Blood samples were collected before and at various time points after dosing on day 1,
166 and urine samples were collected within specific time periods. On days 3-7, blood
167 samples were collected before and 12 hours after dosing. On day 8, both blood and
168 urine samples were collected according to the respective time schedules on day 1. The
169 samples were treated and stored for analysis by liquid chromatography/mass
170 spectrometry at -70°C .

171 *2.3. Supportive in vitro transport and metabolism studies*

172 *2.3.1. Transport study using Caco-2 cell monolayers*

173 The membrane permeability of Dahuang compounds, including chrysophanol (**1**;
174 $5\ \mu\text{mol/L}$), emodin-8-*O*- β -D-glucoside (**2**; $50\ \mu\text{mol/L}$), rhein (**3**; $5\ \mu\text{mol/L}$),
175 chrysophanol-8-*O*- β -D-glucoside (**4**; $50\ \mu\text{mol/L}$), emodin (**5**; $5\ \mu\text{mol/L}$),
176 physcion-8-*O*- β -D-glucoside (**6**; $50\ \mu\text{mol/L}$), chrysophanol-1-*O*- β -D-glucoside (**7**; 50
177 $\mu\text{mol/L}$), physcion (**8**; $5\ \mu\text{mol/L}$), rhein-8-*O*- β -D-glucoside (**9**; $50\ \mu\text{mol/L}$),
178 methylisorhein (**10**; $5\ \mu\text{mol/L}$), and aloe-emodin (**11**; $5\ \mu\text{mol/L}$), was assessed using
179 Caco-2 cell monolayers. The cells were cultured and the integrity of the cell
180 monolayers was measured. The apparent permeability coefficient (P_{app}) of each test

181 compound was calculated ([Supplementary Materials and methods](#)). The test
182 compounds were classified into three categories based on their P_{app} values: low,
183 intermediate, or high membrane permeability [21]. The efflux ratio (EfR) was
184 calculated and used to determine the possible involvement of a transporter-mediated
185 efflux mechanism. Verapamil, MK571, and novobiocin were added to inhibit ABC
186 transporters multidrug resistance protein 1 (MDR1), multidrug resistance-associated
187 protein 2 (MRP2), and breast cancer resistance protein (BCRP). Atenolol and
188 antipyrine were used as low and high permeability reference compounds, respectively,
189 while rhodamine 123, sulfasalazine, and estrone-3-sulfate were used as probe
190 substrates of MDR1, MRP2, and BCRP, respectively. The experimental details have
191 been previously described [31].

192 2.3.2. Transport studies using cells transfected with SLC transporters or membrane 193 vesicles expressing ABC transporters

194 Cellular uptake of chrysophanol (**1**; 5 $\mu\text{mol/L}$), emodin-8-*O*- β -D-glucoside (**2**; 50
195 $\mu\text{mol/L}$), rhein (**3**; 5 $\mu\text{mol/L}$), chrysophanol-8-*O*- β -D-glucoside (**4**; 50 $\mu\text{mol/L}$),
196 emodin (**5**; 5 $\mu\text{mol/L}$), physcion-8-*O*- β -D-glucoside (**6**; 50 $\mu\text{mol/L}$),
197 chrysophanol-1-*O*- β -D-glucoside (**7**; 50 $\mu\text{mol/L}$), physcion (**8**; 5 $\mu\text{mol/L}$),
198 rhein-8-*O*- β -D-glucoside (**9**; 50 $\mu\text{mol/L}$), methylisorhein (**10**; 5 $\mu\text{mol/L}$), aloe-emodin
199 (**11**; 5 $\mu\text{mol/L}$), gallic acid (**42**; 5 $\mu\text{mol/L}$), and 4-*O*-methylgallic acid (**M42_{M2}**; 5
200 $\mu\text{mol/L}$) was assessed using human apical sodium-dependent bile acid transporter
201 (ASBT)-, taurine transporter (TAUT)-, organic anion-transporting polypeptide 2B1
202 (OATP2B1)-, organic anion transporter 1 (OAT1)-, OAT2-, OAT3-, OAT4-, organic

203 cation transporter 2 (OCT2)-, peptide transporter 1 (PEPT1)-, and PEPT2-transfected
204 HEK-293 cells. In addition, vesicular transport of **3** (5 $\mu\text{mol/L}$) and **10** (5 $\mu\text{mol/L}$)
205 was assessed using vesicles expressing human MDR1, BCRP, MRP1, MRP2, MRP3,
206 or MRP4. All the incubation samples were analyzed by liquid chromatography/mass
207 spectrometry. The experimental details have been previously described [32, 33].

208 2.3.3. Metabolism studies

209 The deglycosylation of emodin-8-*O*- β -D-glucoside (**2**),
210 chrysophanol-8-*O*- β -D-glucoside (**4**), physcion-8-*O*- β -D-glucoside (**6**),
211 chrysophanol-1-*O*- β -D-glucoside (**7**), or rhein-8-*O*- β -D-glucoside (**9**), each at 1
212 $\mu\text{mol/L}$, was assessed using recombinant human LPH. Glucuronidation, sulfation, and
213 oxidation of rhein (**3**) or methylisorhein (**10**), each at 1 $\mu\text{mol/L}$, were assessed using
214 UDPGA-fortified HLM, PAPS-fortified HLC, and NADPH-fortified HLM. The
215 detailed incubation conditions were described previously [30].

216 2.4. Supportive rat pharmacokinetic studies

217 Rat pharmacokinetic study on LianhuaQingwen capsule was conducted at
218 Laboratory Animal Center of Shanghai Institute of Materia Medica (Shanghai, China).
219 Three studies were approved by the Institutional Animal Care and Use Committee,
220 following the Guidelines for Ethical Treatment of Laboratory Animals by the Ministry
221 of Science and Technology of China. Femoral artery cannulation or bile duct
222 cannulation was performed to collect rat blood or bile, respectively [23]. In these
223 three rat studies, all the rats were given an oral dose of LianhuaQingwen at 3.78 g/kg.

224 The first study involved the collection of serial blood samples before and at various
225 time points after dosing. The blood samples were treated and centrifuged to produce
226 plasma samples. The second study involved the collection of serial urine samples
227 within specific time periods after dosing. The third study involved the collection of
228 serial bile samples within specific time periods after dosing. The samples were stored
229 for analysis by liquid chromatography/mass spectrometry at -70°C .

230 *2.5. Assay for composition analysis of Dahuang constituents in LianhuaQingwen*

231 The composition analysis of LianhuaQingwen for constituents originating from
232 the component Dahuang was conducted using liquid chromatography/mass
233 spectrometry. A literature-derived list of candidate compounds was used to guide the
234 analysis, and a comprehensive detection approach was employed to identify all
235 constituents present in the sample. The detected constituents underwent
236 characterization and quantification for ranking and grading. Fourteen capsule lots
237 were analyzed to assess inter-lot variability.

238 *2.6. Bioanalytical assays for analyses of Dahuang compounds and other study* 239 *compounds*

240 The pharmacokinetics of Dahuang compounds in LianhuaQingwen
241 administration was investigated through two types of bioanalyses. The first type
242 involved profiling unchanged and metabolized Dahuang compounds in human/rat
243 samples. This was accomplished utilizing the Acquity ultra performance liquid
244 chromatographic separation module/Waters Synapt G2 mass spectrometer to detect,

245 characterize, and quantify the compounds. The second type involved quantifying
246 specific Dahuang compounds in human/rat samples and *in vitro* samples using an
247 Applied Biosystems Sciex Triple Quad 5500 mass spectrometer interfaced with an
248 Agilent 1290 Infinity II LC system. The concentrations of various reference
249 compounds in *in vitro* study samples were analyzed using liquid
250 chromatography/mass spectrometry. Assay validation, implemented according to the
251 European Medicines Agency Guideline on bioanalytical method validation (2012),
252 demonstrated that the quantification assays developed were reliable and reproducible
253 for the intended use, despite no internal standard being used.

254 *2.7. In vitro assessment of SARS-CoV-2 3CL^{pro} protease inhibition*

255 The proteolytic activity of the 3-chymotrypsin-like protease (3CL^{pro}) of
256 SARS-CoV-2 was assessed with a fluorescence resonance energy transfer (FRET)
257 assay. The activity of recombinant SARS-CoV-2 3CL^{pro} was evaluated in cleaving a
258 synthetic fluorogenic peptide substrate MCA-AVLQSGFR-Lys(Dnp)-Lys-NH₂, which
259 was derived from the N-terminal auto-cleavage sequence from the viral protease. The
260 cleaved MCA peptide fluorescence was measured by a SpectraMax M2 microplate
261 reader (Molecular Devices; CA, USA) at an excitation wavelength of 325 nm and an
262 emission wavelength of 393 nm. The assay reaction buffer contained 50 mM Tris-HCl
263 (pH 7.3), 1 mM EDTA, and 20 μM peptide substrate. Enzymatic reactions were
264 initiated with the addition of 100 nM SARS-CoV-2 3CL^{pro} and allowed to proceed at
265 37 °C for 10 min (under linear cleavage condition). The Michaelis-Menten constant of
266 the peptide substrate for SARS-CoV-2 3CL^{pro} was measured to determine the
267 substrate concentration used in the following inhibition assessment. Ebselen, a

268 positive inhibitor of SARS-CoV-2 3CL^{pro}, decreased the fluorescence. The inhibition
269 potencies of the test Dahuang compounds, such as rhein (**3**), methylisorhein (**10**),
270 aloe-emodin (**11**), 4-*O*-methylgallic acid (**M42_{M2}**), and gallic acid (**42**), were initially
271 screened at a concentration of 100 μmol/L. The Dahuang compounds that showed ≥
272 50% inhibition in the initial screening were further evaluated at multiple
273 concentrations for their half-maximal inhibitory concentrations (IC₅₀) for
274 SARS-CoV-2 3CL^{pro}. For the IC₅₀ assessment, the recombinant protease was
275 incubated with the peptide substrate at 1.4 μmol/L (the *K_m* for SARS-CoV-2 3CL^{pro})
276 in the presence or absence of the test Dahuang compound.

277 2.8. Western blot

278 HEK-293 cells were transfected with empty vector, human Flag-ASTB, human
279 Flag-TAUT, rat Flag-ASBT, or rat Flag-TAUT plasmids for 48 hours. After that, the
280 cells were harvested and lysed with RIPA lysis buffer (pH 7.5) containing 150 mM
281 NaCl, 1 mM Na₃VO₄, 50 mM Tris-HCl, 25 mM NaF, 1% NP-40, 0.5% sodium
282 deoxycholate, 0.1% SDS, and 1% phosphatase inhibitor cocktails. Rat lung, bronchus,
283 liver, and intestine were collected and lysed in the same RIPA lysis buffer using a
284 grinder. Subsequently, 20 μg of the aforementioned proteins were loaded onto
285 SDS-PAGE and transferred to nitrocellulose membranes (Millipore, Billerica, MA,
286 USA). The membranes were then incubated overnight at 4°C with primary antibodies
287 against ASBT (1:1000, 25245-1-AP; Proteintech, Wuhan, Hubei Province, China) or
288 TAUT (1:1000, PA5-98161; Invitrogen, Waltham, MA, USA). For detection, the
289 membranes were treated with secondary antibodies conjugated to horseradish

290 peroxidase (Jackson, West Grove, PA, USA) and the immunoreactive proteins were
291 visualized using the West Pico PLUS Chemiluminescent Substrate (Thermo, Waltham,
292 MA, USA) and imaged using chemiluminescent imaging.

293 *2.9. Immunohistochemistry*

294 Rat lung and intestine tissues were fixed in 4% paraformaldehyde and embedded
295 in paraffin. The tissues were then sectioned into 5 μm thick paraffin sections and
296 deparaffinized. Antigen retrieval was performed using Tris-EDTA (pH 9.0). For
297 immunohistochemistry staining, the sections were incubated with primary antibodies
298 against ASBT (1:100, AB203205; Abcam, Cambridge, UK) or TAUT (1:500,
299 PA5-98161; Invitrogen, Waltham, MA, USA), followed by incubation with
300 biotinylated goat anti-rabbit IgG as secondary antibodies. Signals were amplified
301 using a DAB kit (Maixin Bio, Fuzhou, Fujian Province, China) and counterstained
302 with hematoxylin.

303 *2.10. Data Processing*

304 After conducting the composition analysis, the detected and characterized
305 Dahuang constituents were ranked and graded into different levels based on their
306 daily doses. The daily compound dose was calculated by multiplying the compound
307 level in LianhuaQingwen and the capsule's label daily dose of 4.2 g/day.
308 Noncompartmental analysis was used to estimate pharmacokinetic parameters of
309 Dahuang compounds. Renal clearance ratio (R_{rc}) was calculated using renal clearance,
310 glomerular filtration rate [34], and unbound fraction in human plasma. Data are
311 expressed as mean \pm standard deviation, and statistical analysis was performed using

312 a two-tailed unpaired Student t-test. A value of $P < 0.05$ was considered statistically
313 significant.

314 **3. Results**

315 *3.1. Constituents originating from Dahuang and their abundance in LianhuaQingwen*

316 Based on the composition analysis conducted, a total of 55 constituents that
317 originated from the Dahuang component were detected and characterized in samples
318 of LianhuaQingwen (Fig. 1 and Table S3). These constituents were divided into eight
319 classes, including anthraquinones (1–22), anthrones (31–34), tannins (41–52),
320 flavonoids (61–64), naphthalenes (71–73), stilbenes (81–84), pyranones (91–94), and
321 phenylbutanones (101 and 102). All of these constituents had a compound dose of \geq
322 0.01 $\mu\text{mol/day}$. Notably, these constituents were not detected in any other components
323 of LianhuaQingwen, except for gallic acid (42) which was also detected in the
324 component Hongjingtian (*R. crenulata* rhizomes and roots). The major constituents of
325 Dahuang were identified as chrysophanol (1), emodin-8-*O*- β -D-glucoside (2), rhein
326 (3), chrysophanol-8-*O*- β -D-glucoside (4), emodin (5), and
327 physcion-8-*O*- β -D-glucoside (6). These major constituents had a compound dose of
328 1.0–2.2 $\mu\text{mol/day}$. Moreover, LianhuaQingwen also exhibited lot-to-lot variations of
329 8.3%–12.1% for the major anthraquinones (1–6) and 6.6%–55.3% for the rest of the
330 minor constituents.

331 **(Insert Figure 1 here)**

332 *3.2. Major circulating Dahuang compounds after dosing LianhuaQingwen and their*
333 *plasma pharmacokinetics: interspecies differences between humans and rats*

334 Only two classes of compounds, i.e., anthraquinones and tannins, had significant
335 systemic exposure in humans following administration of LianhuaQingwen (Fig. 2
336 and Table 1), despite the presence of 55 Dahuang constituents of eight classes in the
337 capsule. Human systemic exposure to anthraquinones varied greatly, with unchanged
338 rhein (**3**) and methylisorhein (**10**), rather than their metabolites, being the most
339 abundant in circulation. The other anthraquinones, including chrysophanol (**1**),
340 emodin-8-*O*- β -D-glucoside (**2**), chrysophanol-8-*O*- β -D-glucoside (**4**), emodin (**5**),
341 physcion-8-*O*- β -D-glucoside (**6**), chrysophanol-1-*O*- β -D-glucoside (**7**), physcion (**8**),
342 rhein-8-*O*- β -D-glucoside (**9**), and aloe-emodin (**11**), were either not detectable or
343 present in negligible levels in human plasma, either as unchanged compounds or
344 metabolites. The major circulating compound of tannins was 4-*O*-methylgallic acid
345 (**M42_{M2}**), which was a methylated metabolite of gallic acid (**42**), while **42** and its
346 other methylated metabolite 3-*O*-methylgallic acid (**M42_{M1}**) were detected at low
347 levels in plasma (Fig. 2). All circulating compounds were also detected in human
348 urine.

349 **(Insert Figure 2 and Table 1 here)**

350 The data presented in Fig. 2 highlights significant differences in the exposure
351 profile of Dahuang anthraquinones between rats and humans when they received
352 LianhuaQingwen. Although rhein (**3**) and methylisorhein (**10**) were the major
353 circulating anthraquinones for both rats and humans, rats had additional circulating
354 anthraquinones and their metabolites that either went undetected or were present in
355 limited quantities in human plasma. These newly detected anthraquinones in rats

356 included chrysophanol (**1**), chrysophanol-1-*O*-glucuronide (**M1_{G1}**),
357 chrysophanol-8-*O*-glucuronide (**M1_{G2}**), rhein-*O*-glucuronide (**M3_{G1}**),
358 emodin-3-*O*-glucuronide (**M5_{G3}**), physcion-1-*O*-glucuronide (**M8_{G1}**), and
359 physcion-8-*O*-glucuronide (**M8_{G2}**). The major circulating compound in humans for
360 tannins was 4-*O*-methylgallic acid (**M42_{M2}**), while both **M42_{M2}** and gallic acid (**42**)
361 were the major circulating compounds in rats. These findings suggest that the
362 systemic exposure to anthraquinones and tannins could differ considerably between
363 rats and humans, and that such differences should be taken into account when
364 evaluating the safety and efficacy of the Dahuang-containing herbal medicine in
365 preclinical studies.

366 [Table 2](#) summarizes the plasma pharmacokinetics of major circulating Dahuang
367 compounds [rhein (**3**), methylisorhein (**10**), and 4-*O*-methylgallic acid (**M42_{M2}**)] in
368 humans who were given 12 capsules/day of LianhuaQingwen. As illustrated in [Fig. 3](#),
369 both **3** and **10** showed unimodal plasma concentration-time profiles, reaching their
370 peak concentrations (T_{peak}) between 1 and 3 h. Females had a higher C_{max} and
371 AUC_{0-24h} for both **3** and **10** compared to males ($P < 0.05$), with all the data adjusted
372 for body weight. There was no significant accumulation of **3** and **10** after
373 administering LianhuaQingwen for seven consecutive days ($P > 0.05$). As shown in
374 [Table 2](#), renal clearance ratio (R_{rc}) of **3** and **10** suggested that the renal excretion
375 involved tubular secretion, which was mediated by the renal basolateral SLC uptake
376 transporters OAT1, OAT2, and OAT3 ([Tables 3](#) and [S4](#)). In addition, **10**, but not **3**,
377 was also a substrate of the renal apical SLC uptake transporter OAT4, which could

378 induce tubular reabsorption of **10**. The plasma concentration-time profiles of **M42_{M2}**
379 were similar to those of **3** and **10**, as demonstrated in [Table 2](#) and [Fig. 3](#). The R_{tc} of
380 **M42_{M2}** in [Table 2](#) showed that its renal excretion involved tubular secretion, which
381 was also mediated by OAT1, OAT2, and OAT3 ([Table 3](#)).

382 **(Insert Figure 3 and Tables 2 and 3 here)**

383 *3.3 Factors governing the differential human systemic exposure to Dahuang*
384 *anthraquinones: transporter-mediated intestinal absorption and LPH-mediated*
385 *pre-absorption metabolism*

386 Membrane permeability was assessed using Caco-2 cell monolayer to understand
387 the factors governing differential human systemic exposure to the anthraquinones.
388 Rhein (**3**) and methylisorhein (**10**) showed moderate membrane permeability ([Table 4](#)).
389 Estimated water solubility of these two compounds ([Table S5](#)), in relation to their
390 respective compound doses from LianhuaQingwen and Caco-2-based permeability,
391 was insufficient to achieve adequate intestinal absorption [[35](#), [36](#)]. Intestinal
392 penetration of **3** and **10** could also be limited by human intestinal apical MDR1-,
393 BCRP-, and MRP2-mediated efflux into the intestinal lumen ([Table 4](#) and [Table S6](#)).
394 However, human intestinal apical ASBT and TAUT could enhance intestinal
395 absorption of these compounds into intestinal epithelia ([Table 3](#)), and human intestinal
396 basolateral MRP1, MRP3, and MRP4 could mediate the compounds' efflux into blood
397 ([Table S6](#)). Rhein-8-*O*- β -D-glucoside (**9**), which had poor membrane permeability for
398 intestinal absorption, was not a substrate of ASBT or TAUT. However, this

399 anthraquinone glucoside was found to be a substrate of human intestinal LPH, which
400 could facilitate the pre-absorption deglycosylation of **9** into the absorbable **3**. *In vitro*
401 metabolism studies suggested that **3** and **10** were resistant to human hepatic
402 glucuronidation, sulfation, or oxidation (Fig. S1).

403 **(Insert Figure 4 and Table 4 here)**

404 In terms of the other anthraquinone constituents with a compound dose of > 0.3
405 $\mu\text{mol/day}$, emodin-8-*O*-glucoside (**2**) and physcion (**8**) were found to have poor
406 membrane permeability, which limited their passive intestinal absorption. Although
407 chrysophanol (**1**), chrysophanol-8-*O*-glucoside (**4**), emodin (**5**),
408 physcion-8-*O*-glucoside (**6**), chrysophanol-1-*O*-glucoside (**7**), and aloe-emodin (**11**)
409 showed high or intermediate permeability, **1**, **5**, **6**, and **11** exhibited poor water
410 solubility, which could limit their passive intestinal absorption (Table S5).
411 Additionally, their pre-absorption deglycosylation by human intestinal LPH
412 transforming **4** and **7** into unabsorbable **1** and the efflux action of intestinal apical
413 transporters on them restricted their passive intestinal penetration (Table 4). None of
414 these compounds was a substrate of ASBT or TAUT (Table 3).

415 *3.4. Inhibitory activities, against SARS-CoV-2 3CL^{pro}, of circulating Dahuang*
416 *compounds and other circulating compounds of LianhuaQingwen*

417 Rhein (**3**) and methylisorhein (**10**) inhibited 3CL^{pro} of SARS-CoV-2 with IC₅₀
418 values of 4.6 and 37.2 $\mu\text{mol/L}$, respectively (Fig. 5). However, despite being tested at
419 100 $\mu\text{mol/L}$, other Dahuang compounds, such as 4-*O*-methylgallic acid (**M42M2**),

420 gallic acid (**42**), and aloe-emodin (**11**), showed less than 50% inhibition of the viral
421 protease. Furthermore, following our prior and ongoing pharmacokinetic
422 investigations on LianhuaQingwen, we singled out several LianhuaQingwen
423 compounds originating from the capsule's other components and subjected them to
424 SARS-CoV-2 3CL^{PRO} inhibition tests. These compounds, unchanged or metabolized,
425 were glycyrrhetic acid, 24-hydroxyglycyrrhetic acid, ephedrine, pseudoephedrine,
426 hydroxytyrosol-3-*O*-sulfate, hydroxytyrosol, phillygenin, phillygenin-*O*-sulfate,
427 pinoselinol, and menthol-1-*O*-glucuronide and showed less than 50% inhibition of the
428 viral protease, despite being tested at 100 µmol/L.

429 **(Insert Figure 5 here)**

430 *3.5. Expression and cellular localization of Taut and Asbt in rat intestine and lung*

431 The specificity of the anti-TAUT and anti-ASBT antibodies was assessed using
432 Western Blot analysis. HEK-293 cells expressing human TAUT, human ASBT, rat
433 Taut, or rat Asbt with a Flag-tag were used for the experiment. The Flag-tag antibody
434 successfully detected all four plasmids, confirming their expression in the cells. The
435 anti-ASBT antibody recognized both human ASBT and rat Asbt, showing a band at
436 40 kDa. Similarly, the anti-TAUT antibody detected a band at 65 kDa for both human
437 TAUT and rat Taut ([Fig. 6A](#)). These findings validate the reliability of the anti-ASBT
438 and anti-TAUT antibodies in detecting human ASBT/Asbt and TAUT/Taut proteins,
439 respectively. Furthermore, the protein expression levels of Asbt and Taut were
440 examined in rat intestine, liver, and lung tissues using Western Blot analysis with

441 anti-ASBT and anti-TAUT antibodies. Both proteins were detected in the bronchus,
442 lung, liver, and intestine tissues of rats (Fig. 6B). Rat Asbt showed high expression in
443 the bronchus, while Taut exhibited high expression in the liver. Additionally,
444 immunohistochemical analysis was performed on rat lung and intestine tissues. In the
445 bronchial epithelia, rat Asbt was primarily localized on the basolateral membrane,
446 whereas rat Taut was extensively found in the alveolar epithelia and basolateral
447 membrane of bronchial epithelia. Both Asbt and Taut were found in the apical
448 membrane of epithelia in the intestinal villi (Fig. 6C).

449 **(Insert Figure 6)**

450 **4. Discussion**

451 For a complex Chinese herbal medicine, only a few key constituents with
452 drug-like properties are bioavailable at loci responsible for the medicine's therapeutic
453 action, as opposed to all constituents [21]. Multi-compound pharmacokinetic
454 investigation is a useful approach to accurately identify such potential herbal
455 compounds without any omissions, relying on thorough comprehension of the
456 medicine's chemical composition [37]. Such bioavailability of LianhuaQingwen
457 compounds was investigated to evaluate the medicine's efficacy and safety in treating
458 acute viral respiratory illnesses with respect to their systemic exposure and targeted
459 reachability within the body [20]. As part of our multi-compound pharmacokinetic
460 researches on LianhuaQingwen, the previous investigation found that the major
461 circulating Gancao compounds, glycyrrhetic acid and 24-hydroxyglycyrrhetic acid (a
462 new Gancao metabolite), could reach and inhibit renal distal tubular
463 11β -hydroxysteroid dehydrogenase type 2, a target responsible for Gancao-induced
464 pseudoaldosteronism [20]. In the current investigation, a comprehensive analysis
465 conducted and identified a total of 55 Dahuang constituents ($\geq 0.01 \mu\text{mol/day}$) in
466 LianhuaQingwen. However, among these constituents, only three exhibited
467 significant systemic exposure in humans after dosing the capsule. These three
468 constituents were the anthraquinones rhein (**3**) and methylisorhein (**10**; a new
469 Dahuang anthraquinone), and the tannin 4-*O*-methylgallic acid (**M42_{M2}**). Interestingly,
470 the levels of the remaining anthraquinones and their metabolites, such as
471 chrysophanol (**1**), emodin (**5**), physcion (**8**), and aloe-emodin (**11**), were either
472 undetectable or found in very low quantities in human plasma. This significant
473 variation in systemic exposure to Dahuang anthraquinones could be attributed to two

474 main factors: transporter-mediated intestinal absorption and LPH-mediated
475 pre-absorption metabolism. Dahuang anthraquinones, including **3** and **10**, have poor
476 water solubility, low membrane permeability, and/or intestinal apical efflux. These
477 properties hindered their passive absorption in the intestine, meaning they could not
478 easily cross the intestinal membrane on their own. However, in the case of **3** and **10**,
479 the human intestinal apical uptake transporters ASBT and TAUT, as well as the
480 human intestinal basolateral efflux transporters MRP1/3/4, could mediate their
481 intestinal absorption and resulted in their significant systemic exposure in human after
482 dosing the capsule. It should be noted that other Dahuang anthraquinones did not
483 exhibit human ASBT- or TAUT-mediated absorption. Additionally, the enzyme LPH
484 present in the human intestinal epithelia played a crucial role in facilitating the
485 transformation of rhein-8-*O*- β -D-glucoside (**9**) into readily absorbable **3**. Interestingly,
486 this enzyme also transformed chrysophanol-8-*O*- β -D-glucoside (**4**) and
487 chrysophanol-1-*O*- β -D-glucoside (**7**) into a non-absorbable **1**, despite their favorable
488 characteristics of being highly water-soluble and easily permeable.

489 In addition to systemic exposure, targeted reachability of rhein (**3**) and
490 methylisorhein (**10**) was also an important factor for the efficacy of LianhuaQingwen
491 capsule, a medication used in China to treat viral respiratory illnesses, including
492 severe acute respiratory syndrome (SARS), Middle East respiratory syndrome
493 (MERS), and coronavirus disease 2019 (COVID-19). Infections of SARS-CoV,
494 MERS-CoV, and SARS-CoV-2 could cause severe respiratory pathologies and lung
495 injuries by infecting bronchial epithelial cells and pneumocytes in humans [38, 39].
496 Therefore, it was crucial for the treatment to specifically target the lungs. The 3CL^{pro}
497 enzyme, due to its essential role in viral replication and high degree of conservation
498 across all coronaviruses, as well as its absence in human homologs, has been

499 identified as an attractive target for the development of drug against coronaviruses
500 such as SARS-CoV-2 [38, 40]. Rhein (**3**) and methylisorhein (**10**) demonstrated the
501 ability to inhibit this enzyme, with IC₅₀ values of 4.6 and 37.2 μmol/L, respectively
502 (Fig. 5). Like their human counterparts, TAUT and ASBT, mentioned above in the
503 context of intestinal absorption of **3** and **10**, rat Taut and rat Asbt was also found to
504 transport these two compounds (Fig. S2). The mRNA of human TAUT was found to
505 be widely expressed in various human tissues, such as the lungs, kidneys, and liver,
506 due to the recognized role of taurine, an endogenous substrate of TAUT, as an organic
507 osmolyte [41, 42]. In contrast, ASBT mRNA was exclusively detected in the human
508 ileum and kidney [43, 44]. Furthermore, the ASBT protein was found to be
509 predominantly located on the apical membrane of enterocytes in the human terminal
510 ileum [44, 45]. The intestinal TAUT and ASBT was considered a favorite target for
511 developing "drug inhibitor" to regulate the levels of bile acids, cholesterol, lipids, and
512 glucose, or "drug substrate" to improve its oral bioavailability [46, 47]. Although the
513 precise localization of human TAUT and human ASBT proteins in lung epithelia
514 remains unclear, their rat orthologues, Asbt and Taut, was observed in alveolar
515 epithelia and the basolateral membrane of rat bronchial epithelia, as well as the apical
516 membrane of epithelia in the intestinal villi in this investigation (Fig. 6). The uptake
517 of circulating **3** and **10** into lung epithelia could be expected to exert their potential
518 antiviral effects in humans. By targeting the lung epithelia and inhibiting the viral
519 protease enzyme in humans, these two compounds had the potential to combat
520 respiratory illnesses caused by coronaviruses such as SARS-CoV-2. Collectively,
521 systemic exposure to and targeted reachability of **3** and **10** could be significant factors
522 in the efficacy of LianhuaQingwen capsule. Further research on pulmonary
523 localizations and genetic variations of TAUT and ASBT in humans will provide

524 additional insights into the mechanisms underlying the antiviral effects of **3** and **10**.

525 It is worth noting that systemic exposure to Dahuang anthraquinones and tannins
526 may vary considerably between rats and humans after dosing LianhuaQingwen. While
527 rhein (**3**) and methylisorhein (**10**) were the primary anthraquinones found in both rat
528 and human plasma, rats exhibited additional circulating anthraquinones and their
529 metabolites, including rhein-*O*-glucuronide (**M3_{G1}**), that were either undetected or
530 present in limited quantities in human plasma. In humans, the principal circulating
531 compound for tannins was 4-*O*-methylgallic acid (**M42_{M2}**), while both **M42_{M2}** and
532 gallic acid (**42**) were the major circulating compounds in rats. Glucuronidation was
533 the main metabolic pathway of anthraquinones, including **3**, in rats after dosing a
534 Dahuang extract, while methylation was the main metabolic pathway of gallic acid
535 [48, 49]. Rhein was reported the only compound that humans were significantly
536 exposed to after orally dosing a Dahuang extract [50]. To date, the pharmacokinetic
537 mechanisms governing its significant systemic exposure, including its glucuronidation,
538 remain unclear in humans. Our investigation revealed that, apart from rhein being
539 absorbed in the intestines through human ASBT/TAUT-mediated intestinal uptake
540 from the intestinal lumen and human MRP1/3/4-mediated intestinal efflux into the
541 blood, poor metabolism of **3** in humans was found to be another factor contributing to
542 its significant systemic exposure. This was evident from our observation that there
543 was no significant difference in the systemic exposure to total **3** (including both free
544 and conjugated forms) and free **3** in humans after oral administration of
545 LianhuaQingwen (Fig. S3). This finding was further supported by the observed poor
546 *in vitro* human hepatic glucuronidation, sulfation, and oxidation of **3** (Fig. S1).
547 Methylisorhein (**10**) exhibited a similar situation in humans. The intestinal absorption
548 of **3** and **10** in rats was also mediated by rat orthologues of human ASBT and human

549 TAUT. However, the molecular mechanisms by which other Dahuang anthraquinones
550 and their metabolites were significantly exposed in rats remain unclear. Due to
551 practical and ethical concerns associated with human experimentation, the use of
552 animal models, specifically rats and mice, has become essential in antiviral research.
553 These models are crucial for evaluating the safety and efficacy of antiviral drugs, in
554 addition to conducting in vitro studies on their antiviral activities. Safety concerns
555 arised due to the presence of the quinone moiety in the structure of these
556 anthraquinones. Studies have focused on the potential hepatotoxicity of Dahuang,
557 specifically investigating its anthraquinones and tannins[6]. However, these
558 investigations have primarily relied on preclinical models, especially rat models [6,
559 51]. Even when assessing the toxicity of specific compounds like **3**, the doses needed
560 to induce toxicity were considerably higher than the typical doses used in clinical
561 settings [51]. Therefore, such interspecies differences in systemic exposure to
562 Dahuang anthraquinones should be taken into account when evaluating the safety and
563 efficacy of the Dahuang-containing herbal medicine in preclinical studies. Further
564 research is needed to fully understand the implications of the interspecies differences
565 associated with molecular mechanisms, in order to accurately assess its potential
566 benefits and risks in humans.

567 In the field of herbal medicine, anthraquinones are found in a diverse range of
568 plant species, particularly in the families *Polygonaceae* (such as the Chinese
569 medicinal herb Dahuang), *Fabaceae* (Juemingzi and Fanxieye), and *Rubiaceae*
570 (Qiecao). Anthraquinones can be present in these herbs both in their free form as
571 aglycones (like rhein) and bound to sugar residues (like rhein-8-*O*- β -D-glucoside).
572 The quantity of free and glycosylated anthraquinones in herbal medicines can be
573 affected by factors like the specific origin, variety, and processing methods of the

574 component herb. These variations in the active constituents of the herb can affect
575 quality and efficacy of the herbal medicines. For example, in the case of Dahuang,
576 which includes the rhizomes and roots of *R. palmatum* L., *R. tanguticum* Maxim. ex
577 Balf., and *R. officinale* Baill. from the *Polygonaceae* family, the ratio of free and
578 glycosylated rhein content can vary greatly, ranging from 0.001 to 65 [52]. In herbal
579 medicines rich in β -glycosylated anthraquinones, lactase or lactase-phlorizin
580 hydrolase (LPH, EC 3.2.1.23/62) plays a significant role in the hydrolysis of
581 β -glycosylated anthraquinones to free anthraquinones (Fig. 4). This was demonstrated
582 by the significant systemic exposure of free rhein (rather than
583 rhein-8-*O*- β -D-glucoside), with a short T_{max} value of 0.5 h, in rats after oral
584 administration of rhein-8-*O*- β -D-glucoside (Fig. S4). LPH is a primary β -glycosidase
585 located in the intestinal microvillus membrane and is responsible for the extracellular
586 hydrolysis of most β -glycosylated xenobiotics, such as glycosylated flavonoids [53].
587 This hydrolase is predominantly expressed in the jejunum, with lower levels of
588 expression in the proximal and distal ends of the intestines [54]. When the activity of
589 intestinal LPH becomes inhibited or decreased, β -glycosylated anthraquinones reach
590 the colon. It is presumed that the colonic concentration of free anthraquinones
591 increased, resulting in a higher likelihood of inducing local drug effects. This can be
592 attributed to the presence of colonic microbiota and the absence of intestinal uptake
593 transporters, such as ABST [44, 45]. Therefore, by understanding the content and
594 extraction of free and glycosylated anthraquinones in herbal medicines, as well as the
595 role of LPH in their hydrolysis, researchers can better comprehend the potential
596 therapeutic effects and mechanisms of action of these anthraquinone-containing
597 medicinal plants.

598

599 **5. Conclusion**

600 In this investigation, we examined systemic exposure and targeted reachability of
601 Dahuang compounds in humans through a multi-compound pharmacokinetic
602 investigation of a Dahuang-containing medicine LianhuaQingwen. During the
603 investigation, 55 constituents (≥ 0.01 $\mu\text{mol/day}$), originating from Dahuang (*R.*
604 *palmatum* rhizomes and roots), were identified and characterized in LianhuaQingwen.
605 However, only three Dahuang compounds - rhein (**3**), methylisorhein (**10**), and
606 4-*O*-methylgallic acid (**M42_{M2}**) - exhibited significant systemic exposure in humans
607 after dosing the capsule. Two absorption mechanisms for **3** and **10** across the small
608 intestine have been proposed: active intestinal uptake of **3** and **10** by human
609 ASBT/TAUT and human MRP1/3/4, and gut-luminal hydrolysis of
610 rhein-8-*O*- β -D-glucoside (**9**) by LPH, followed by the absorption of released **3** by the
611 intestinal transporters. Another contributing factor to their significant systemic
612 exposure was the poor metabolism of **3** and **10** in humans. In contrast, the other
613 anthraquinones and their metabolites were either undetectable or present in low
614 concentrations in human plasma. This can be attributed to their poor water solubility,
615 low membrane permeability, and/or intestinal apical efflux, which hindered their
616 absorption in the intestines. Additionally, targeted reachability of circulating **3** and **10**
617 could be achieved as rat orthologues of human ASBT/TAUT was observed in alveolar
618 epithelia and basolateral membrane of bronchial epithelia, where coronaviruses could
619 infect and replicate. These two compounds showed potential ability to inhibit the
620 3CL^{pro} enzyme responsible for viral replication in coronaviruses. This suggested that
621 the compounds had potential use in treating respiratory illnesses caused by
622 coronaviruses. It is important to note that the circulating Dahuang anthraquinones and

623 tannins differed significantly between humans and rats after dosing LianhuaQingwen.
624 This highlights the significance of considering interspecies differences when
625 evaluating the safety and efficacy of the Dahuang-containing medicines. Overall, this
626 investigation, along with similar studies on other components, contributes to defining
627 the therapeutic benefits of Dahuang-containing medicines. It also underscores the
628 need to establish conditions for the safe use of these medicines by considering
629 interspecies differences.

630 **CRedit author statement**

631 **Nan-Nan Tian:** Investigation, Validation, Formal analysis, Visualization;
632 **Ling-Ling Ren:** Investigation, Validation, Formal analysis, Visualization; **Ya-Xuan**
633 **Zhu:** Investigation, Validation, Formal analysis; **Jing-Ya Sun:** Investigation, Formal
634 analysis, Visualization; **Jun-Lan Lu:** Investigation, Validation; **Jia-Kai Zeng:**
635 Investigation, Validation; **Feng-Qing Wang:** Investigation; **Fei-Fei Du:** Investigation;
636 **Xi-He Yang:** Investigation; **Shu-Ning Ge:** Investigation; **Rui-Min Huang:**
637 Conceptualization, Methodology, Formal analysis; **Wei-Wei Jia:** Investigation,
638 Validation, Formal analysis, Visualization, Conceptualization, Methodology, Writing -
639 Original draft preparation, Reviewing and Editing, Project administration, Funding
640 acquisition; **Chuan Li:** Conceptualization, Methodology, Formal analysis, Writing -
641 Original draft preparation, Reviewing and Editing, Supervision, Funding acquisition.

642 **Declaration of competing interest**

643 The authors declare that there are no conflicts of interest.

644 **Acknowledgements**

645 This work was funded by grants from the National Natural Science Foundation
646 of China (Grant Nos.: 82074176 and 81503345), Innovation Team and Talents
647 Cultivation Program of National Administration of Traditional Chinese Medicine
648 (Grant No.: ZYYCXTD-C-202009), and the National Key R&D Program of China
649 (Grant No.: 2018YFC1704500).

650 **Appendix A. Supplementary data**

651

652 References

- 653 [1]. H. Xiang, J.X. Zuo, F.Y. Guo, et al. What we already know about rhubarb: a comprehensive
654 review, *Chinese Medicine* 15 (2020).
- 655 [2]. China Pharmacopoeia Commission. *Chinese Pharmacopoeia*. Beijing, China: China Medical
656 Science Press; 2020:24-25.
- 657 [3]. K. Huang, P. Zhang, Z. Zhang, et al. Traditional Chinese Medicine (TCM) in the treatment of
658 COVID-19 and other viral infections: Efficacies and mechanisms, *Pharmacol Ther* 225 (2021)
659 107843.
- 660 [4]. W. Luo, X. Su, S. Gong, et al. Anti-SARS coronavirus 3C-like protease effects of *Rheum*
661 *palmatum* L. extracts, *Biosci Trends* 3 (2009) 124-126.
- 662 [5]. S. Das, A. Singh, S.K. Samanta, et al. Naturally occurring anthraquinones as potential inhibitors of
663 SARS-CoV-2 main protease: an integrated computational study, *Biologia (Bratisl)* 77 (2022)
664 1121-1134.
- 665 [6]. T. Zhuang, X. Gu, N. Zhou, et al. Hepatoprotection and hepatotoxicity of Chinese herb Rhubarb
666 (*Dahuang*): How to properly control the "General (Jiang Jun)" in Chinese medical herb, *Biomed*
667 *Pharmacother* 127 (2020) 110224.
- 668 [7]. E.M. Clementi, F. Misiti. Potential health benefits of rhubarb. *Bioactive foods in promoting health:*
669 Elsevier; 2010:407-423.
- 670 [8]. F. Zhang, R. Wu, Y.F. Liu, et al. Nephroprotective and nephrotoxic effects of Rhubarb and their
671 molecular mechanisms, *Biomedicine & Pharmacotherapy* 160 (2023).
- 672 [9]. J.B. Wang, W.J. Kong, H.J. Wang, et al. Toxic effects caused by rhubarb (*Rheum palmatum* L.) are
673 reversed on immature and aged rats, *J Ethnopharmacol* 134 (2011) 216-220.
- 674 [10]. Chinese National Health Commission and Chinese State Administration of Traditional Chinese
675 Medicine. Diagnosis and treatment plan for influenza (2019 version). 2019.
676 ([http://www.nhc.gov.cn/yzygj/s7653p/201911/a577415af4e5449cb30ecc6511e369c7/files/75a810](http://www.nhc.gov.cn/yzygj/s7653p/201911/a577415af4e5449cb30ecc6511e369c7/files/75a810713dc14dcd9e6db8b654bdef79.pdf)
677 [713dc14dcd9e6db8b654bdef79.pdf](http://www.nhc.gov.cn/yzygj/s7653p/201911/a577415af4e5449cb30ecc6511e369c7/files/75a810713dc14dcd9e6db8b654bdef79.pdf))
- 678 [11]. National Health and Family Planning Commission of People's Republic of China. Guideline on
679 diagnosis and treatment of Middle East respiratory syndrome (2015 version). *Chin J Viral Dis* 5
680 (2015) 352-354.
- 681 [12]. K. Hu, W.J. Guan, Y. Bi, et al. Efficacy and safety of Lianhuaqingwen capsules, a repurposed
682 Chinese herb, in patients with coronavirus disease 2019: A multicenter, prospective, randomized
683 controlled trial, *Phytomedicine* 85 (2021) 153242.
- 684 [13]. L. Zhang, L. Wu, X. Xu, et al. Effectiveness of Lianhua Qingwen Capsule in Treatment of
685 Asymptomatic COVID-19 Patients: A Randomized, Controlled Multicenter Trial, *J Integr*
686 *Complement Med* 28 (2022) 887-894.
- 687 [14]. P. Shen, J. Li, S. Tu, et al. Positive effects of Lianhuaqingwen granules in COVID-19 patients: A
688 retrospective study of 248 cases, *J Ethnopharmacol* 278 (2021) 114220.
- 689 [15]. S.J. Fan, J.K. Liao, L. Wei, et al. Treatment efficacy of Lianhua Qingwen capsules for early-stage
690 COVID-19, *Am J Transl Res* 14 (2022) 1332-1338.
- 691 [16]. J. Wu, Q. Wang, L. Yang, et al. Potency of Lianhua Qingwen granule combined with paramivir
692 sodium chloride injection in treating influenza and level changes of serum inflammatory factors,
693 *Am J Transl Res* 13 (2021) 6790-6795.
- 694 [17]. L. Runfeng, H. Yunlong, H. Jicheng, et al. Lianhuaqingwen exerts anti-viral and
695 anti-inflammatory activity against novel coronavirus (SARS-CoV-2), *Pharmacol Res* 156 (2020)
696 104761.

- 697 [18].X. Chen, Y. Wu, C. Chen, et al. Identifying potential anti-COVID-19 pharmacological components
698 of traditional Chinese medicine Lianhuaqingwen capsule based on human exposure and ACE2
699 bi chromatography screening, *Acta Pharm Sin B* 11 (2021) 222-236.
- 700 [19].C. Li, W.W. Jia, J.L. Yang, et al. Multi-compound and drug-combination pharmacokinetic research
701 on Chinese herbal medicines, *Acta Pharmacol Sin* 43 (2022) 3080-3095.
- 702 [20].X.F. Lan, O.E. Olaleye, J.L. Lu, et al. Pharmacokinetics-based identification of
703 pseudoaldosterogenic compounds originating from *Glycyrrhiza uralensis* roots (Gancao) after
704 dosing LianhuaQingwen capsule, *Acta Pharmacol Sin* 42 (2021) 2155-2172.
- 705 [21].T. Lu, J. Yang, X. Gao, et al. Plasma and urinary tanshinol from *Salvia miltiorrhiza* (Danshen) can
706 be used as pharmacokinetic markers for cardiotonic pills, a cardiovascular herbal medicine, *Drug*
707 *Metab Dispos* 36 (2008) 1578-1586.
- 708 [22].H. Liu, J. Yang, F. Du, et al. Absorption and disposition of ginsenosides after oral administration
709 of *Panax notoginseng* extract to rats, *Drug Metab Dispos* 37 (2009) 2290-2298.
- 710 [23].F. Chen, L. Li, F. Xu, et al. Systemic and cerebral exposure to and pharmacokinetics of flavonols
711 and terpene lactones after dosing standardized *Ginkgo biloba* leaf extracts to rats via different
712 routes of administration, *Br J Pharmacol* 170 (2013) 440-457.
- 713 [24].Z. Hu, J. Yang, C. Cheng, et al. Combinatorial metabolism notably affects human systemic
714 exposure to ginsenosides from orally administered extract of *Panax notoginseng* roots (Sanqi),
715 *Drug Metab Dispos* 41 (2013) 1457-1469.
- 716 [25].M. Li, F. Wang, Y. Huang, et al. Systemic exposure to and disposition of catechols derived from
717 *Salvia miltiorrhiza* roots (Danshen) after intravenous dosing DanHong injection in human subjects,
718 rats, and dogs, *Drug Metab Dispos* 43 (2015) 679-690.
- 719 [26].C. Cheng, F. Du, K. Yu, et al. Pharmacokinetics and Disposition of Circulating Iridoids and
720 Organic Acids in Rats Intravenously Receiving ReDuNing Injection, *Drug Metab Dispos* 44 (2016)
721 1853-1858.
- 722 [27].C. Cheng, J.Z. Lin, L. Li, et al. Pharmacokinetics and disposition of monoterpene glycosides
723 derived from *Paeonia lactiflora* roots (Chishao) after intravenous dosing of antiseptic XueBiJing
724 injection in human subjects and rats, *Acta Pharmacol Sin* 37 (2016) 530-544.
- 725 [28].X. Li, C. Cheng, F. Wang, et al. Pharmacokinetics of catechols in human subjects intravenously
726 receiving XueBiJing injection, an emerging antiseptic herbal medicine, *Drug Metab*
727 *Pharmacokinet* 31 (2016) 95-98.
- 728 [29].X.W. Liu, J.L. Yang, W. Niu, et al. Human pharmacokinetics of ginkgo terpene lactones and
729 impact of carboxylation in blood on their platelet-activating factor antagonistic activity, *Acta*
730 *Pharmacol Sin* 39 (2018) 1935-1946.
- 731 [30].N. Zhang, C. Cheng, O.E. Olaleye, et al. Pharmacokinetics-Based Identification of Potential
732 Therapeutic Phthalides from XueBiJing, a Chinese Herbal Injection Used in Sepsis Management,
733 *Drug Metab Dispos* 46 (2018) 823-834.
- 734 [31].J.Y. Dai, J.L. Yang, C. Li. Transport and metabolism of flavonoids from Chinese herbal remedy
735 Xiaochaihu- tang across human intestinal Caco-2 cell monolayers, *Acta Pharmacol Sin* 29 (2008)
736 1086-1093.
- 737 [32].W. Jia, F. Du, X. Liu, et al. Renal tubular secretion of tanshinol: molecular mechanisms, impact on
738 its systemic exposure, and propensity for dose-related nephrotoxicity and for renal herb-drug
739 interactions, *Drug Metab Dispos* 43 (2015) 669-678.
- 740 [33].R. Jiang, J. Dong, X. Li, et al. Molecular mechanisms governing different pharmacokinetics of
741 ginsenosides and potential for ginsenoside-perpetrated herb-drug interactions on OATP1B3, *Br J*
742 *Pharmacol* 172 (2015) 1059-1073.
- 743 [34].B. Davies, T. Morris. Physiological parameters in laboratory animals and humans, *Pharm Res* 10
744 (1993) 1093-1095.

- 745 [35].C.A. Lipinski. Drug-like properties and the causes of poor solubility and poor permeability, *J*
746 *Pharmacol Toxicol Methods* 44 (2000) 235-249.
- 747 [36].W. Curatolo. Physical chemical properties of oral drug candidates in the discovery and exploratory
748 development settings, *Pharmaceutical Science & Technology Today* 1 (1998) 387-393.
- 749 [37].C. Li, C. Cheng, W. Jia, et al. Multi-compound pharmacokinetic research on Chinese herbal
750 medicines: identifying potentially therapeutic compounds and characterizing their disposition and
751 pharmacokinetics, *Acta Pharmaceutica Sinica* 56 (2021) 2426-2446.
- 752 [38].P. V'Kovski, A. Kratzel, S. Steiner, et al. Coronavirus biology and replication: implications for
753 SARS-CoV-2, *Nat Rev Microbiol* 19 (2021) 155-170.
- 754 [39].M.Z. Tay, C.M. Poh, L. Renia, et al. The trinity of COVID-19: immunity, inflammation and
755 intervention, *Nat Rev Immunol* 20 (2020) 363-374.
- 756 [40].K. Anand, J. Ziebuhr, P. Wadhvani, et al. Coronavirus main proteinase (3CLpro) structure: basis
757 for design of anti-SARS drugs, *Science* 300 (2003) 1763-1767.
- 758 [41].S. Ramamoorthy, F.H. Leibach, V.B. Mahesh, et al. Functional characterization and chromosomal
759 localization of a cloned taurine transporter from human placenta, *Biochem J* 300 (Pt 3) (1994)
760 893-900.
- 761 [42].P. Singh, K. Gollapalli, S. Mangiola, et al. Taurine deficiency as a driver of aging, *Science* 380
762 (2023) eabn9257.
- 763 [43].A.L. Craddock, M.W. Love, R.W. Daniel, et al. Expression and transport properties of the human
764 ileal and renal sodium-dependent bile acid transporter, *Am J Physiol* 274 (1998) G157-169.
- 765 [44].M. Drozdziak, C. Groer, J. Penski, et al. Protein abundance of clinically relevant multidrug
766 transporters along the entire length of the human intestine, *Mol Pharm* 11 (2014) 3547-3555.
- 767 [45].P. Hruz, C. Zimmermann, H. Gutmann, et al. Adaptive regulation of the ileal apical sodium
768 dependent bile acid transporter (ASBT) in patients with obstructive cholestasis, *Gut* 55 (2006)
769 395-402.
- 770 [46].M. Li, Q. Wang, Y. Li, et al. Apical sodium-dependent bile acid transporter, drug target for bile
771 acid related diseases and delivery target for prodrugs: Current and future challenges, *Pharmacol*
772 *Ther* 212 (2020) 107539.
- 773 [47].D. Stary, M. Bajda. Taurine and Creatine Transporters as Potential Drug Targets in Cancer Therapy,
774 *International Journal of Molecular Sciences* 24 (2023) 3788.
- 775 [48].R. Song, L. Xu, F. Xu, et al. In vivo metabolism study of rhubarb decoction in rat using
776 high-performance liquid chromatography with UV photodiode-array and mass-spectrometric
777 detection: a strategy for systematic analysis of metabolites from traditional Chinese medicines in
778 biological samples, *J Chromatogr A* 1217 (2010) 7144-7152.
- 779 [49].C.S. Shia, S.H. Juang, S.Y. Tsai, et al. Metabolism and pharmacokinetics of anthraquinones in
780 *Rheum palmatum* in rats and ex vivo antioxidant activity, *Planta Med* 75 (2009) 1386-1392.
- 781 [50].J.H. Lee, J.M. Kim, C. Kim. Pharmacokinetic analysis of rhein in *Rheum undulatum* L, *J*
782 *Ethnopharmacol* 84 (2003) 5-9.
- 783 [51].Y. Xu, X. Mao, B. Qin, et al. In vitro and in vivo metabolic activation of rhein and characterization
784 of glutathione conjugates derived from rhein, *Chem Biol Interact* 283 (2018) 1-9.
- 785 [52].K. Komatsu, Y. Nagayama, K. Tanaka, et al. Comparative study of chemical constituents of
786 rhubarb from different origins, *Chem Pharm Bull (Tokyo)* 54 (2006) 1491-1499.
- 787 [53].H. Elferink, J.P.J. Bruckers, G.H. Veeneman, et al. A comprehensive overview of substrate
788 specificity of glycoside hydrolases and transporters in the small intestine : "A gut feeling", *Cell*
789 *Mol Life Sci* 77 (2020) 4799-4826.
- 790 [54].J.T. Troelsen. Adult-type hypolactasia and regulation of lactase expression, *Biochim Biophys Acta*
791 1723 (2005) 19-32.

792
793**Table 1**
Dahuang compounds, unchanged and metabolized, detected in human samples after orally dosing LianhuaQingwen.

Compound (ID)	LC/TOF-MS ^E data				Molecular formula	Presence in human samples
	<i>t</i> _R (min)	[M-H] ⁻ (<i>m/z</i>)	Mass error (ppm)	Fragmentation profile (<i>m/z</i>)		
Chrysophanol (1)	27.14	253.0511	4.0	225.0569, 183.0091	C ₁₅ H ₁₀ O ₄	Plasma, urine
Chrysophanol-1- <i>O</i> -glucuronide (M1_{G1})	19.24	429.0815	-1.6	253.0507, 225.0492, 183.0077	C ₂₁ H ₁₈ O ₁₀	Plasma, urine
Chrysophanol-8- <i>O</i> -glucuronide (M1_{G2})	19.41	429.0822	0	253.0505, 225.0708, 183.0178	C ₂₁ H ₁₈ O ₁₀	Plasma, urine
Emodin- <i>O</i> -β-D-glucoside (2)	18.94	431.0966	-2.8	269.0443, 225.1192	C ₂₁ H ₂₀ O ₁₀	Plasma
Rhein (3)	23.61	283.0247	1.4	239.0348, 211.0422, 183.0411	C ₁₅ H ₁₈ O ₆	Plasma, urine
Rhein- <i>O</i> -glucuronide-1 (M3_{G1})	15.23	459.0563	-0.2	283.0244, 239.0339	C ₂₁ H ₁₆ O ₁₂	Plasma, urine
Rhein- <i>O</i> -glucuronide-2 (M3_{G2})	16.93	459.0555	-2.0	283.0234, 239.0352	C ₂₁ H ₁₆ O ₁₂	Urine
Emodin (5)	26.01	269.0455	1.9	241.0667, 225.0515, 197.0307	C ₁₅ H ₁₀ O ₅	Plasma, urine
Emodin- <i>O</i> -glucuronide (M5_{G2})	19.53	445.0764	-1.6	269.0394, 225.0772	C ₂₁ H ₁₈ O ₁₁	Plasma, urine
Emodin-3- <i>O</i> -glucuronide (M5_{G3})	21.24	445.0776	1.1	269.0451, 225.0622	C ₂₁ H ₁₈ O ₁₁	Plasma, urine
Physcion (8)	28.60	283.0605	-0.4	240.0323	C ₁₆ H ₁₂ O ₅	Urine
Physcion-1- <i>O</i> -glucuronide (M8_{G1})	20.92	459.0924	-0.7	283.0599	C ₂₂ H ₂₀ O ₁₁	Plasma
Physcion-8- <i>O</i> -glucuronide (M8_{G2})	21.42	459.0923	-0.9	283.0607	C ₂₂ H ₂₀ O ₁₁	Plasma, urine
Methylisorhein (10)	21.93	297.0392	-2.4	253.0485	C ₁₆ H ₁₀ O ₆	Plasma, urine
Aloe-emodin (11)	21.81	269.0457	2.6	240.0364, 211.1301, 183.0977	C ₁₅ H ₁₀ O ₅	Plasma, urine
Gallic acid (42)	3.73	169.0137	0	125.0227, 78.9810	C ₇ H ₆ O ₅	Plasma, urine
3- <i>O</i> -Methylgallic acid (M42_{M1})	7.65	183.0297	2.2	168.0056, 139.0397, 124.0153	C ₈ H ₈ O ₅	Plasma, urine
4- <i>O</i> -Methylgallic acid (M42_{M2})	8.05	183.0299	3.3	168.0064, 139.0371, 124.0163	C ₈ H ₈ O ₅	Plasma, urine
2,5-Dimethyl-7-hydroxychrome (91)	16.38	189.0556	2.1	174.0307, 146.0338	C ₁₁ H ₁₀ O ₃	Plasma, urine

The details of human and rat studies and bioanalytical assay are described in the [Supplementary Materials and methods](#).

794
795**Table 2**
Pharmacokinetics of rhein (**3**), methylisorhein (**10**), and 4-*O*-methylgallic acid (**M42M2**) in volunteers orally receiving LianhuaQingwen.

Pharmacokinetics	On day 1		On day 8	
	Male (m1–m8)	Female (f9–f14)	Male (m1–m8)	Female (f9–f14)
<i>Rhein (2)</i>				
C_{\max} (nmol/L)	239.9 ± 68.6	286.7 ± 65.7	149.5 ± 30.6	277.0 ± 153.7
T_{peak} (h)	2.5 ± 0.9	3.0 ± 0	3.1 ± 1.4	2.7 ± 0.8
AUC _{0–24h} (h·nmol/L)	1469.3 ± 362.0	2103.9 ± 629.6	1013.3 ± 328.8	1933.6 ± 910.7
AUC _{0–∞} (h·nmol/L)	1494.1 ± 368.9	2168.8 ± 659.2	1050.4 ± 370.3	2006.5 ± 934.9
MRT (h)	6.9 ± 1.2	7.5 ± 1.7	7.4 ± 1.6	7.6 ± 1.6
$t_{1/2}$ (h)	3.8 ± 0.7	4.8 ± 2.1	4.6 ± 0.8	4.2 ± 0.6
$Cum.A_{e-U,0-48h}$ (nmol/kg)	7.9 ± 2.5	9.4 ± 3.9	8.5 ± 3.4	7.1 ± 1.9
CL _R (mL/h/kg)	5.6 ± 1.6	4.6 ± 1.8	9.0 ± 4.7	4.5 ± 2.6
R_{rc}	5.3 ± 1.5	4.3 ± 1.7	8.4 ± 4.3	4.2 ± 2.4
<i>Methylisorhein (10)</i>				
C_{\max} (nmol/L)	84.0 ± 16.5	126.6 ± 25.6	50.3 ± 11.0	115.2 ± 66.4
T_{peak} (h)	4.5 ± 1.6	4.0 ± 1.5	4.9 ± 2.2	5.5 ± 2.3
AUC _{0–24h} (h·nmol/L)	899.9 ± 180.2	1342.4 ± 339.3	624.3 ± 181.7	1210.6 ± 497.6
AUC _{0–∞} (h·nmol/L)	1128.8 ± 264.6	1659.0 ± 486.6	767.2 ± 232.1	1418.2 ± 596.3
MRT (h)	15.4 ± 3.0	17.8 ± 3.9	16.8 ± 2.4	13.8 ± 2.1
$t_{1/2}$ (h)	9.5 ± 1.7	9.3 ± 1.3	9.1 ± 1.3	7.9 ± 0.7
$Cum.A_{e-U,0-48h}$ (nmol/kg)	2.0 ± 0.8	3.6 ± 1.2	3.1 ± 1.4	3.6 ± 1.2
CL _R (mL/h/kg)	2.2 ± 0.8	2.8 ± 1.1	5.5 ± 3.1	3.4 ± 1.8
R_{rc}	2.1 ± 0.8	2.6 ± 1.0	5.1 ± 2.9	3.2 ± 1.7
<i>4-O-Methylgallic acid (M42M2)</i>				
C_{\max} (nmol/L)	119.0 ± 32.6	139.3 ± 32.7	96.7 ± 13.2	80.4 ± 21.2
T_{peak} (h)	3.0 ± 0	2.7 ± 0.8	3.0 ± 0	3.0 ± 0
AUC _{0–24h} (h·nmol/L)	463.0 ± 90.7	538.1 ± 99.4	341.6 ± 54.3	318.6 ± 86.3
AUC _{0–∞} (h·nmol/L)	466.7 ± 91.0	540.1 ± 100.4	349.7 ± 55.9	320.7 ± 86.6
MRT (h)	4.3 ± 0.4	3.8 ± 0.5	4.4 ± 0.5	4.0 ± 0.4
$t_{1/2}$ (h)	1.4 ± 0.2	1.2 ± 0.4	1.9 ± 0.3	1.3 ± 0.3
$Cum.A_{e-U,0-48h}$ (nmol/kg)	55.9 ± 19.9	86.7 ± 25.8	53.9 ± 14.2	46.9 ± 25.2
CL _R (mL/h/kg)	124.6 ± 49.3	159.6 ± 34.2	162.2 ± 49.8	142.6 ± 63.6

R_{fc}	2.8 ± 1.1	3.6 ± 0.8	3.6 ± 1.1	3.2 ± 1.4
----------	---------------	---------------	---------------	---------------

796 C_{max} , maximum plasma concentration; T_{peak} , the time taken to achieve the peak plasma concentration; AUC, area under the plasma concentration-time curve after dosing;
797 MRT, mean residence time; $t_{1/2}$, terminal half-life; $Cum.A_{e-U}$, cumulative amount excreted into urine; CL_R , renal excretory clearance.

798 **Table 3**
 799 Passive diffusion of Dahuang compounds in mock HEK-293 cells and their net transport ratios in HEK-293 cells transfected with various human intestinal or renal
 800 transporters.

Compound (ID)	Transport in mock cell ($\mu\text{L}/\text{min}/\text{mg}$ protein)	Net transport ratio									
		TAUT	ASBT	OATP2B1	PEPT1	OAT1	OAT2	OAT3	OAT4	OCT2	PEPT2
Positive substrate	—	7.2 ± 1.5	200 ± 38	12.3 ± 2.4	17.6 ± 2.1	476 ± 57	24.1 ± 3.6	4.5 ± 0.3	7.6 ± 1.3	14.5 ± 2.6	54.9 ± 3.9
Chrysophanol (1)	8.8 ± 1.1	1.0 ± 0.1	0.9 ± 0.5	0.9 ± 0.3	2.2 ± 0.2	—	—	—	—	—	—
Emodin-8- <i>O</i> - β -D-glucoside (2)	0.1 ± 0.0	2.1 ± 0.3	0.8 ± 0.1	3.6 ± 0.1	0.9 ± 0.1	—	—	—	—	—	—
Rhein (3)	0.2 ± 0.0	18.4 ± 2.7	5.9 ± 0.7	1.0 ± 0	0.7 ± 0.1	9.9 ± 1.0	8.4 ± 0.3	1.1 ± 0.1	1.8 ± 0.3	1.0 ± 0.2	1.7 ± 0.3
Chrysophanol-8- <i>O</i> - β -D-glucoside (4)	1.5 ± 0.2	0.8 ± 0.1	1.4 ± 0.1	2.0 ± 0.4	0.8 ± 0.1	—	—	—	—	—	—
Emodin (5)	27.8 ± 1.6	1.0 ± 0.1	1.7 ± 0.4	1.6 ± 0.1	0.8 ± 0.2	—	—	—	—	—	—
Physcion-8- <i>O</i> - β -D-glucoside (6)	6.0 ± 1.2	0.7 ± 0.1	1.0 ± 0.3	1.2 ± 0.2	0.8 ± 0.1	—	—	—	—	—	—
Chrysophanol-1- <i>O</i> - β -D-glucoside (7)	1.4 ± 0.1	1.3 ± 0.4	1.2 ± 0.1	0.7 ± 0	1.5 ± 0.6	—	—	—	—	—	—
Physcion (8)	9.4 ± 2.4	0.8 ± 0.1	1.8 ± 0.4	1.1 ± 0.1	1.2 ± 0.2	—	—	—	—	—	—
Rhein-8- <i>O</i> - β -D-glucoside (9)	0.02 ± 0	0.8 ± 0.1	0.7 ± 0.4	0.7 ± 0	0.9 ± 0.1	—	—	—	—	—	—
Methylisorhein (10)	0.1 ± 0.0	7.7 ± 0.4	3.1 ± 0.3	2.4 ± 0.1	2.2 ± 0.1	8.1 ± 0.6	11.8 ± 0.3	5.7 ± 0.0	4.9 ± 1.1	1.3 ± 0.1	1.2 ± 0.3
Aloe-emodin (11)	24.8 ± 3.1	1.1 ± 0.3	1.2 ± 0.2	1.0 ± 0.1	1.4 ± 0.2	—	—	—	—	—	—
Gallic acid (42)	0.01 ± 0	1.1 ± 0.2	1.2 ± 0.4	1.6 ± 0.5	0.5 ± 0	—	—	—	—	—	—
4- <i>O</i> -methylgallic acid (M42_{M2})	0.03 ± 0	—	—	—	0.9 ± 0.3	73.2 ± 3.3	20.1 ± 0.8	5.5 ± 0.6	1.5 ± 0.1	0.6 ± 0.2	1.1 ± 0.2

801 For assessment of cellular uptake mediated by intestinal or renal transporters, differential transport rates between transfected cells and mock cells were defined as a net
 802 transport ratio, which represents the mean \pm standard deviation ($n = 3$). A net transport ratio > 3 suggested a positive result. Positive substrates were taurocholic acid (ASBT),
 803 [H^3]-taurine (TAUT), estrone-3-sulfate (OATP2B1/OAT3/OAT4), glycylsarcosine (PEPT1/PEPT2), *para*-aminohippuric acid (OAT1), prostaglandin F_{2a} (OAT2),
 804 tetraethylammonium (OCT2) and their final concentrations were $20 \mu\text{mol}/\text{L}$ with incubation time of 10 min.

805
806

Table 4
Apparent permeability for the investigational Dahuang compounds in Caco-2 cell monolayers.

Compound	Without inhibitors			With inhibitors		
	P_{app} ($\times 10^{-6}$ cm/s)		EfR	P_{app} ($\times 10^{-6}$ cm/s)		EfR
	Apical→Basolateral	Basolateral→Apical		Apical→Basolateral	Basolateral→Apical	
Atenolol	0.8 ± 0.1	0.7 ± 0.1	0.9	—	—	—
Antipyrine	33.1 ± 7.8	36.6 ± 6.4	1.1	—	—	—
Rhodamine 123	0.8 ± 0.1	10.9 ± 1.2	14.0	0.3 ± 0.0	0.6 ± 0.0	1.9
Sulfasalazine	0.6 ± 0.0	10.7 ± 1.7	17.5	0.8 ± 0.0	1.6 ± 0.1	1.9
Estrone-3-sulfate	0.8 ± 0.2	7.4 ± 0.1	9.3	1.7 ± 0.1	1.4 ± 0.1	0.8
Chrysophanol (1)	2.0 ± 0.5	3.9 ± 0.1	2.0	—	—	—
Emodin-8- <i>O</i> - β -D-glucoside (2)	0.2 ± 0.0	2.7 ± 0.2	14.8	0.3 ± 0.1	0.9 ± 0.0	2.8
Rhein (3)	5.5 ± 0.6	34.2 ± 1.8	6.3	7.8 ± 0.9	17.0 ± 4.7	2.2
Chrysophanol-8- <i>O</i> - β -D-glucoside (4)	6.1 ± 0.2	25.6 ± 7.7	4.2	11.7 ± 0.9	10.2 ± 0.5	0.9
Emodin (5)	18.6 ± 1.3	16.5 ± 4.0	0.9	—	—	—
Physcion-8- <i>O</i> - β -D-glucoside (6)	0.6 ± 0.0	8.9 ± 1.3	14.9	1.2 ± 0.2	4.3 ± 0.9	3.5
Chrysophanol-1- <i>O</i> - β -D-glucoside (7)	3.8 ± 0.5	22.0 ± 2.0	5.8	9.0 ± 0.2	7.2 ± 2.1	0.8
Physcion (8)	0.4 ± 0.0	0.3 ± 0.0	0.9	—	—	—
Rhein-8- <i>O</i> - β -D-glucoside (9)	0.3 ± 0.0	0.3 ± 0.1	1.1	—	—	—
Methylisorhein (10)	1.4 ± 0.1	34.0 ± 3.7	24.0	4.0 ± 1.4	10.6 ± 2.3	2.6
Aloe-emodin (11)	37.1 ± 3.6	32.4 ± 2.2	0.9	—	—	—

807 Antipyrine, high permeability reference compound; atenolol, low permeability reference compound; rhodamine 123, P-gp probe substrate; sulfasalazine, MRP2 probe
808 substrate; estrone-3-sulfate, BCRP probe substrate. Inhibitors, the mixture of verapamil (P-gp inhibitor), MK571 (MRP2 inhibitor), and novobiocin (BCRP inhibitor). An
809 efflux ratio (EfR) greater than 3 was considered as a positive result, suggesting that the investigational compound was an *in vitro* substrate of efflux transporter(s).

810 **Figure captions:**

811 **Fig. 1.** LianhuaQingwen constituents originating from Dahuang. (A) stacked liquid
812 chromatograms of anthraquinones (1–22), anthrones (31–34), tannins (41–52),
813 flavonoids (61–64), naphthalenes (71–73), stilbenes (81–84), pyranones (91–94), and
814 phenylbutanones (101 and 102), detected by mass spectrometry, in a typical sample of
815 LianhuaQingwen; (B) constituents detected in a sample of raw material of Dahuang
816 (*Rheum palmatum* rhizomes and roots); (C) mean content levels of the constituents
817 detected in samples of 14 lots of LianhuaQingwen; (D) daily doses of the constituents
818 from the lot A1802055 of LianhuaQingwen at the label daily dose 4.2 g/day; (E)
819 percentage daily doses of anthraquinones, anthrones, tannins, flavonoids,
820 naphthalenes, stilbenes, pyranones, and phenylbutanones in their respective total daily
821 dose of all the constituents of the class detected in LianhuaQingwen. **1**, chrysophanol;
822 **2**, emodin-8-*O*- β -D-glucoside; **3**, rhein; **4**, chrysophanol-8-*O*- β -D-glucoside; **5**,
823 emodin; **6**, physcion-8-*O*- β -D-glucoside; and **10**, methylisorhein. The names of the
824 other 48 constituents originating from Dahuang are shown in [Table S3](#). The details of
825 composition analysis of LianhuaQingwen for constituents originating from Dahuang
826 are described in the [Supplementary Materials and methods](#).

827 **Fig. 2.** Dahuang compounds detected in healthy volunteers and rats after orally dosing
828 LianhuaQingwen. (A and C) systemic exposure data; (B and D) renal excretion data;
829 (E) hepatobiliary excretion data. The dose for human volunteers was 12
830 capsules/person (A and B), while that for rats was 3.78 g/kg (C–E). Both unchanged
831 and metabolized Dahuang compounds were detected. **3**, rhein; **10**, methylisorhein,
832 **M42_{M2}**, 4-*O*-methylgallic acid. The names of the other Dahuang compounds detected
833 are shown in [Table 1](#).

834 **Fig. 3** Plasma concentration-time profiles of rhein (A and B), methylisorhein (C and
835 D), and 4-*O*-methylgallic acid (E and F) in volunteers after dosing LianhuaQingwen

836 at 12 capsules/person. Solid dots, data of males; Open dots, data of females.
837 Pharmacokinetic data of these compounds are shown [Table 2](#).

838 **Fig. 4** *In vitro* human LPH-mediated deglycosylation of Dahuang anthraquinone
839 glycosides. LPH-mediated deglycosylation of the positive substrate phlorizin to
840 phloretin (A) and Dahuang compounds emodin-8-*O*- β -D-glucoside to emodin (B),
841 chrysophanol-8-*O*- β -D-glucoside to chrysophanol (C), physcion-8-*O*- β -D-glucoside
842 to physcion (D), chrysophanol-1-*O*- β -D-glucoside to chrysophanol (E), and
843 rhein-8-*O*- β -D-glucoside to rhein (F). Solid dots, glycosides; open dots, aglycones.
844 Other *in vitro* metabolism data of Dahuang compounds are shown in [Supplementary](#)
845 [Fig. S1](#).

846 **Fig. 5** Inhibitory activities against of Dahuang compounds against SARS-CoV-2
847 3CL^{pro}. (A) Percentage inhibition of 3CL^{pro} by circulating Dahuang compounds at 100
848 μ mol/L. (B) IC₅₀ of positive drug ebselen against 3CL^{pro}. (C and D) IC₅₀ of rhein and
849 methylisorhein against 3CL^{pro}, respectively.

850 **Fig. 6** Expression and cellular localization of Taut and Asbt proteins in the rat
851 intestine and lung. (A) Western blot analysis of human ASBT, rat Asbt, human TAUT,
852 or rat Taut proteins in the transfected HEK-293 cells. Representative autoradiographs
853 of the Western blots demonstrating 40-kDa human ASBT and rat Asbt protein bands
854 in the homogenates of human ASBT- and rat Asbt-transfected HEK293 cells,
855 respectively. Similarly, 65-kDa human TAUT and rat Taut proteins are observed in the
856 homogenates of human TAUT- and rat Taut-transfected HEK293 cells, respectively.
857 (B) Western blot analysis of Asbt and Taut proteins in rat lung, liver, and intestine
858 tissues. In the homogenates of these tissues, 40-kDa Asbt protein bands and 65-kDa
859 Taut protein bands are detected in rat bronchus, lung, liver, and intestine. (C)
860 Immunohistochemical localization of Asbt and Taut proteins in rat intestine and lung
861 tissues.

862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904




Fig. 1. LianhuaQingwen constituents originating from Dahuang. (A) stacked liquid chromatograms of anthraquinones (1–22), anthrones (31–34), tannins (41–52), flavonoids (61–64), naphthalenes (71–73), stilbenes (81–84), pyranones (91–94), and phenylbutanones (101 and 102), detected by mass spectrometry, in a typical sample of LianhuaQingwen; (B) constituents detected in a sample of raw material of Dahuang (*Rheum palmatum* rhizomes and roots); (C) mean content levels of the constituents detected in samples of 14 lots of LianhuaQingwen; (D) daily doses of the constituents from the lot A1802055 of LianhuaQingwen at the label daily dose 4.2 g/day; (E) percentage daily doses of anthraquinones, anthrones, tannins, flavonoids, naphthalenes, stilbenes, pyranones, and phenylbutanones in their respective total daily dose of all the constituents of the class detected in LianhuaQingwen. 1, chrysophanol; 2, emodin-8-*O*- β -D-glucoside; 3, rhein; 4, chrysophanol-8-*O*- β -D-glucoside; 5, emodin; 6, physcion-8-*O*- β -D-glucoside; and 10, methylisorhein. The names of the other 48 constituents originating from Dahuang are shown in [Table S3](#). The details of composition analysis of LianhuaQingwen for constituents originating from Dahuang are described in the [Supplementary Materials and methods](#).

905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930




Fig. 2. Dahuang compounds detected in healthy volunteers and rats after orally dosing LianhuaQingwen. (A and C) systemic exposure data; (B and D) renal excretion data; (E) hepatobiliary excretion data. The dose for human volunteers was 12 capsules/person (A and B), while that for rats was 3.78 g/kg (C–E). Both unchanged and metabolized Dahuang compounds were detected. **3**, rhein; **10**, methylisorhein, **M42M₂**, 4-*O*-methylgallic acid. The names of the other Dahuang compounds detected are shown in Table 1.

931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949




Fig. 3 Plasma concentration-time profiles of Dahuang compounds in volunteers after dosing LianhuaQingwen at 12 capsules/person. (A and B), rhein; (C and D), methylisorhein; (E and F), 4-*O*-methylgallic acid. Solid dots, data of males; Open dots, data of females. Pharmacokinetic data of these compounds are shown [Table 2](#).

950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966




Fig. 4 *In vitro* human LPH-mediated deglycosylation of Dahuang anthraquinone glycosides. Deglycosylation of the positive substrate phlorizin to phloretin (A) and Dahuang compounds emodin-8-*O*- β -D-glucoside to emodin (B), chrysophanol-8-*O*- β -D-glucoside to chrysophanol (C), physcion-8-*O*- β -D-glucoside to physcion (D), chrysophanol-1-*O*- β -D-glucoside to chrysophanol (E), and rhein-8-*O*- β -D-glucoside to rhein (F). Solid dots, anthraquinone glycosides; open dots, the respective free anthraquinones. Other *in vitro* metabolism data of Dahuang compounds are shown in [Supplementary Fig. S1](#).

967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985




Fig. 5 Inhibitory activities against of Dahuang compounds against SARS-CoV-2 3CL^{pro}. (A) Percentage inhibition of 3CL^{pro} by circulating Dahuang compounds at 100 μmol/L. (B) IC₅₀ of positive drug ebselen against 3CL^{pro}. (C and D) IC₅₀ of rhein (**3**) and methylisorhein (**10**) against 3CL^{pro}, respectively.

986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012




Fig. 6 Expression and cellular localization of Taut and Asbt proteins in the rat intestine and lung. (A) Western blot analysis of human ASBT, rat Asbt, human TAUT, or rat Taut proteins in the transfected HEK-293 cells. Representative autoradiographs of the Western blots demonstrating 40-kDa human ASBT and rat Asbt protein bands in the homogenates of human ASBT- and rat Asbt-transfected HEK293 cells, respectively. Similarly, 65-kDa human TAUT and rat Taut proteins are observed in the homogenates of human TAUT- and rat Taut-transfected HEK293 cells, respectively. (B) Western blot analysis of Asbt and Taut proteins in rat lung, liver, and intestine tissues. In the homogenates of these tissues, 40-kDa Asbt protein bands and 65-kDa Taut protein bands are detected in rat bronchus, lung, liver, and intestine. (C) Immunohistochemical localization of Asbt and Taut proteins in rat intestine and lung tissues.